NeuBase Therapeutics Inc. (NBSE) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
350 TECHNOLOGY DRIVE PITTSBURGH, PA 15219 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2023 MRQ | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 23,153 | 52,893 | 31,992 | 10,314 | 3,750 | 12,800 | |||
| Cash and cash equivalents | 23,153 | 52,893 | 31,992 | 10,314 | 3,750 | 12,800 | |||
| Prepaid expense | 563 | 1,452 | 522 | 450 | 248 | 223 | |||
| Asset, held-for-sale, not part of disposal group | |||||||||
| Other undisclosed current assets | 933 | 583 | 295 | 266 | 1 | ||||
| Total current assets: | 24,649 | 54,929 | 32,809 | 11,029 | 3,998 | 13,024 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 104 | 216 | ✕ | ✕ | |||||
| Operating lease, right-of-use asset | 5,615 | 5,945 | ✕ | ✕ | |||||
| Property, plant and equipment | 2,157 | 2,464 | 1,167 | 431 | 16 | 64 | |||
| Long-term investments and receivables | 416 | 324 | 586 | ||||||
| Long-term investments | 416 | 324 | 586 | ||||||
| Intangible assets, net (including goodwill) | 146 | 7,612 | 14,829 | ||||||
| Goodwill | 741 | ||||||||
| Intangible assets, net (excluding goodwill) | 146 | 7,612 | 14,088 | ||||||
| Prepaid expense | 145 | 339 | |||||||
| Other noncurrent assets | 160 | ||||||||
| Other undisclosed noncurrent assets | 170 | 37 | 12 | ||||||
| Total noncurrent assets: | 8,045 | 9,239 | 1,636 | 1,502 | 7,628 | 14,905 | |||
| TOTAL ASSETS: | 32,693 | 64,168 | 34,444 | 12,531 | 11,626 | 27,929 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 4,274 | 3,556 | 2,061 | 1,883 | 652 | 4,828 | |||
| Employee-related liabilities | ✕ | 768 | |||||||
| Accounts payable | 1,843 | 1,808 | 1,505 | 1,477 | |||||
| Accrued liabilities | 1,663 | 1,748 | 556 | 406 | |||||
| Other undisclosed accounts payable and accrued liabilities | 652 | 4,828 | |||||||
| Debt | 108 | 256 | 139 | 123 | 73 | 106 | |||
| Derivative instruments and hedges, liabilities | |||||||||
| Other liabilities | 950 | 496 | |||||||
| Other undisclosed current liabilities | (215) | 383 | |||||||
| Total current liabilities: | 4,166 | 4,194 | 3,150 | 2,502 | 725 | 4,934 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 5,335 | 5,904 | |||||||
| Finance lease, liability | 110 | ✕ | ✕ | ||||||
| Liabilities, other than long-term debt | 150 | ||||||||
| Deferred compensation liability, classified | 150 | ||||||||
| Operating lease, liability | 5,335 | 5,794 | ✕ | ✕ | |||||
| Other undisclosed noncurrent liabilities | (5,335) | (5,794) | |||||||
| Total noncurrent liabilities: | 5,335 | 5,904 | 150 | ||||||
| Total liabilities: | 9,502 | 10,098 | 3,150 | 2,502 | 725 | 5,084 | |||
| Equity | |||||||||
| Equity, attributable to parent | 23,192 | 54,070 | 31,295 | 10,029 | 10,901 | 22,845 | |||
| Common stock | 3 | 3 | 2 | 2 | 6 | 6 | |||
| Additional paid in capital | 125,933 | 123,034 | 74,851 | 37,028 | 132,221 | 130,928 | |||
| Accumulated deficit | (102,744) | (68,968) | (43,559) | (27,000) | (121,326) | (108,089) | |||
| Total equity: | 23,192 | 54,070 | 31,295 | 10,029 | 10,901 | 22,845 | |||
| TOTAL LIABILITIES AND EQUITY: | 32,693 | 64,168 | 34,444 | 12,531 | 11,626 | 27,929 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2023 TTM | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other Income) | 450 | 412 | 150 | |||||
| Gross profit: | 450 | 412 | 150 | |||||
| Operating expenses | (33,318) | (26,565) | (17,069) | (26,336) | (9,819) | (23,851) | ||
| Other undisclosed operating income (loss) | (450) | (412) | (4,235) | 71 | ||||
| Operating loss: | (33,318) | (26,565) | (17,069) | (26,336) | (13,904) | (23,780) | ||
| Nonoperating income (expense) | (458) | 1,156 | (315) | 667 | (31) | |||
| Other nonoperating income (expense) | (167) | 1,156 | (315) | 593 | (1) | |||
| Interest and debt expense | (24) | (32) | (8) | (129) | 1,229 | |||
| Loss from continuing operations: | (33,800) | (25,442) | (17,392) | (26,465) | (12,008) | (23,811) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (33,800) | (25,442) | (17,392) | (26,465) | (12,008) | (23,811) | |
| Net loss: | (33,800) | (25,442) | (17,392) | (26,465) | (12,008) | (23,811) | ||
| Other undisclosed net income (loss) attributable to parent | 24 | 32 | 8 | (493) | (1,229) | |||
| Net loss available to common stockholders, diluted: | (33,776) | (25,409) | (17,385) | (26,958) | (13,237) | (23,811) | ||
Comprehensive Income ($ in thousands)
| 9/30/2023 TTM | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (33,800) | (25,442) | (17,392) | (26,465) | (12,008) | (23,811) | ||
| Comprehensive loss, net of tax, attributable to parent: | (33,800) | (25,442) | (17,392) | (26,465) | (12,008) | (23,811) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.